1
|
Gökmen-Polar Y, Goswami CP, Toroni RA, Sanders KL, Mehta R, Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW. Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. J Cancer 2014; 5:633-45. [PMID: 25157274 PMCID: PMC4142325 DOI: 10.7150/jca.8466] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2014] [Accepted: 06/20/2014] [Indexed: 12/29/2022] Open
Abstract
Bevacizumab, the recombinant antibody targeting vascular endothelial growth factor (VEGF), improves progression-free but not overall survival in metastatic breast cancer. To seek further insights in resistance mechanisms to bevacizumab at the molecular level, we developed VEGF and non-VEGF-driven ER-positive MCF7-derived xenograft models allowing comparison of tumor response at different timepoints. VEGF gene (MV165) overexpressing xenografts were initially sensitive to bevacizumab, but eventually acquired resistance. In contrast, parental MCF7 cells derived tumors were de novo insensitive to bevacizumab. Microarray analysis with qRT-PCR validation revealed that Follistatin (FST) and NOTCH were the top signaling pathways associated with resistance in VEGF-driven tumors (P<0.05). Based on the presence of VEGF, treatment with bevacizumab resulted in altered patterns of metagenes and PAM50 gene expression. In VEGF-driven model after short and long-term bevacizumab treatments, a change in the intrinsic subtype (luminal to myoepithelial/basal-like) was observed in association with increased expression of genes implicated with cancer stem cell phenotype (P<0.05). Our results show that the presence or absence of VEGF expression affects the response to bevacizumab therapy and gene pathways. In particular, long-term bevacizumab treatment shifts the cancer cells to a more aggressive myoepithelial/basal subtype in VEGF-expressing model, but not in non-VEGF model. These findings could shed light on variable results to anti-VEGF therapy in patients and emphasize the importance of patient stratification based on the VEGF expression. Our data strongly suggest consideration of patient subgroups for treatment and designing novel combinatory therapies in the clinical setting.
Collapse
Affiliation(s)
- Yesim Gökmen-Polar
- 1. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN
| | - Chirayu P Goswami
- 2. Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN
| | - Rachel A Toroni
- 3. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
| | - Kerry L Sanders
- 3. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
| | - Rutika Mehta
- 1. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN
| | - Usha Sirimalle
- 1. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN
| | - Bogdan Tanasa
- 4. Scripps Research Institute, University of Medicine and Pharmac, La Jolla, CA
| | - Changyu Shen
- 2. Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN
| | - Lang Li
- 2. Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN
| | - Mircea Ivan
- 3. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
| | - Sunil Badve
- 1. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN; ; 3. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
| | - George W Sledge
- 1. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN; ; 3. Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
2
|
Cano OD, Gökmen-Polar Y, Chirayu G, Li L, Sirimalle U, Gu X, Nakshatri H, Badve S. Abstract 4206: Identification of transcriptional regulatory motifs that control gene expression in premenopausal women with previous history of breast cancer. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-4206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Age is an important risk factor for Breast Cancer. Older women have a 50 times greater risk for breast cancer as compared to younger women (under the age of 30 years). Aging is associated with activation of specific transcription factor networks. We hypothesized that premature activation of these programs may predispose to cancer. The aims of this study were 1) to identify active transcription factor networks controlling the expression of specific cancer-related genes in the normal breast and 2) to analyze whether premature activation of this network is associated with neoplastic transformation. Methods: Fresh frozen normal breast tissue of women, under the age of 50 years, with and without history of breast cancer was obtained (ncancer=8, nnon cancer=4). Total RNA was extracted, cDNA annealed and Whole-genome DASL assay (Illumina Corp) was conducted to identify genes that correlated with cancer outcome in premenopausal women. Differential expression analysis was performed using Partek® software program to identify the up or down regulated genes in women with cancer compared to those without. Transcription factors affecting the regulation of genes in patients with cancer were predicted using MotifModeler program (Liu et al). The resulting data was confirmed using qPCR analysis. Results: Whole genome DASL analysis showed differential expression of 34 genes (p-value <0.01). MotifModeler analysis predicted 18 transcription factors as major regulators of gene expression in premenopausal women with previous history of breast cancer. JUNB and FOS were the most significantly altered in this comparison. qPCR pre-validated the over expression of JUNB and FOS in association with cancer development. Further validation studies in an independent cohort are ongoing using Formalin-fixed Paraffin-embedded (FFPE) samples. Conclusion: Gene expression analysis identified transcriptional features of cancer outcome. Differential expression of the JUNB and FOS family of proteins, which are part of AP-1 transcription factor complex, may be correlated with neoplastic transformation in premenopausal women. Breast Cancer Program of the IU Simon Cancer Center funded this project.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4206. doi:1538-7445.AM2012-4206
Collapse
Affiliation(s)
| | | | | | - Lang Li
- 1Indiana University, Indianapolis, IN
| | | | | | | | | |
Collapse
|
3
|
Gökmen-Polar Y, Toroni RA, Goswami C, Sanders KL, Mehta R, Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW. P5-06-01: Gene Expression Analysis of Resistance to Bevacizumab in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), had promising therapeutic efficacy in breast cancer. However, intrinsic or acquired resistance is common in the clinic. To improve our understanding of the underlying mechanisms of resistance to bevacizumab (BEV), we report the gene expression analysis of resistance to bevacizumab in a VEGF-overexpressing xenograft model of ER-positive breast cancer.
Methods: We developed a nude mouse xenograft model of resistance to anti-VEGF therapy with BEV in which MCF-7 control (ML20) or MCF-7 VEGF (MV165) transfectants were implanted in mammary fat pads, allowed to grow, then treated with BEV, with collection of tumor at early or late time points (while responding (R) to or progressing (NR) on anti-VEGF therapy). To elucidate differentially expressed gene profiling associated with tumor resistance to BEV, we performed whole-genome gene expression analysis (Human WG-6v2 Expression Beadchips, Illumina) and miRNA profiling (TaqMan ***ArrayHuman MicroRNAA+B Cards Set v3.0, Applied Biosystems). Validation of the chosen genes was performed using quantitative real-time RT-PCR (qRT-PCR).
Results: Gene expression analysis revealed differentially regulated genes in the MV165-NR group compared with the MV165-R group. Among the significant genes, Follistatin (FST) and HEY2 were the top genes upregulated in NR compared to R by ANOVA. Expression of HEY2 is induced by the Notch signaling pathway. Using qRT-PCR, we validated the expression of FST and Notch in our system. FST was significantly decreased (Fold change= −3.2; P=0.03) in the R group compared with vehicle in MV165 xenografts. In contrast to R group, FST was upregulated significantly (Fold change= 9.3; P=0.05) in the NR group. Notch4 displayed increased levels of expression in NR group, but it did not reach significance (P=0.23). In addition, correlation of mRNA and miRNA profiles showed that miRNAs targeting FST and Notch4 were differentially regulated in NR group compared to R group in MV165 xenograft tumors. Among the miRNAs, TGF-β-induced oncomiR miR-181a is up-regulated in NR and targets both FST and Notch4. Other miRNAs that target both Notch4 and FST include miR-1, miR-133a, miR-133b, and mir-449b. Conclusion: Our data serve as a potential mechanistic explanation for acquired resistance to bevacizumab. These data may shed light on the transitory effect of BEV observed in the E2100 firstline metastatic breast cancer trial, where VEGF-targeted therapy prolongs progression-free survival in metastatic breast cancer without improving overall survival.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-06-01.
Collapse
Affiliation(s)
- Y Gökmen-Polar
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - RA Toroni
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - C Goswami
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - KL Sanders
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - R Mehta
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - U Sirimalle
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - B Tanasa
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - C Shen
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - L Li
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - M Ivan
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - S Badve
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - GW Sledge
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| |
Collapse
|
4
|
Gökmen-Polar Y, Toroni RA, Goswami C, Sanders KL, Sirimalle U, Mehta R, Li L, Ivan M, Badve S, Sledge GW. P3-04-02: Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-04-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Anti-vascular endothelial growth factor (anti-VEGF) therapy improves disease-free but not overall survival in metastatic breast cancer. To seek further insight on resistance to anti-VEGF antibody bevacizumab (BEV) at the molecular level, we developed breast cancer xenograft models allowing comparison of tumor response at different time-points. Here we report the gene expression and miRNA analyses of response and non-response to BEV in these models.
Methods: MCF-7 cells transfected with control vector (ML20) or VEGF (MV165) were implanted into the mammary fat pads of athymic mice. Tumors from short-term treatment with BEV (3 weeks; Responders to BEV, R) or long-term treatment (8 weeks; Non-Responders, NR) or with vehicle control group (V) were subjected to whole-genome gene expression analysis (Human WG-6v2 Expression Beadchips, Illumina) and miRNA profiling (TaqMan ArrayHuman MicroRNA A+B Cards Set v3.0, Applied Biosystems).Validation of the chosen genes was performed using quantitative real-time RT-PCR (qRT-PCR) and Immunohistochemistry (IHC). Results: Short-term treatment to BEV (3 weeks; 5 mg/kg, i.p./twice weekly) inhibited primary tumor growth significantly in MV165 xenografts compared with vehicle control, whereas BEV treatment did not affect the tumor growth in the ML20 model. MV165 xenografts progressed after 8 weeks of BEV treatment. Gene set enrichment analysis (GSEA) revealed that luminal A-related gene sets were enriched in MV165-R compared to MV165-NR group including DESMEDT (ESR1), SMID_Breast_Cancer_Luminal_A_up, and MASSARWEH_ Tamoxifen_Resistance_ Down. Myoepithelial-specific gene sets were upregulated in both the R and NR groups compared with the vehicle group. qRT-PCR analysis showed that estrogen receptor alpha (ESR1) representative for luminal A decreased significantly in the MV-165-NR group (P=0.001) compared to vehicle. In contrast, Cytokeratin 5 (KRT5) levels increased significantly in both R (P=0.02) and NR (P=0.03) groups. In addition, KRT14 was upregulated in R (P= 0.04) and in NR (P=0.14) group in comparison with the vehicle group, suggesting the upregulation of myoepithelial phenotype specific to BEV treated MV165 model, but not ML20 model. Similar results were obtained by IHC. Consistent with mRNA changes, ESR1 regulated miRNA such as miR-107 (P=0.007) and miRNA important in tamoxifen resistance such as mir-451 (P= 0.0003) were also altered in MV165-NR group compared to vehicle. Conclusion: These results suggest that treatment with BEV may alter the intrinsic subtypes in the presence of VEGF expression. These data may help to explain the variable results to anti-VEGF therapy based on the duration of BEV treatment.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-04-02.
Collapse
Affiliation(s)
| | - RA Toroni
- 1Indiana University School of Medicine, Indianapolis, IN
| | - C Goswami
- 1Indiana University School of Medicine, Indianapolis, IN
| | - KL Sanders
- 1Indiana University School of Medicine, Indianapolis, IN
| | - U Sirimalle
- 1Indiana University School of Medicine, Indianapolis, IN
| | - R Mehta
- 1Indiana University School of Medicine, Indianapolis, IN
| | - L Li
- 1Indiana University School of Medicine, Indianapolis, IN
| | - M Ivan
- 1Indiana University School of Medicine, Indianapolis, IN
| | - S Badve
- 1Indiana University School of Medicine, Indianapolis, IN
| | - GW Sledge
- 1Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|